Bệnh xương trong bệnh thalassemia: mối liên hệ giữa sỏi thận, mật độ khoáng xương và gãy xương

Lauderdale DS, Thisted RA, Wen M, Favus MJ (2001) Bone mineral density and fracture among prevalent kidney stone cases in the third national health and nutrition examination survey. J Bone Miner Res 16:1893–1898 Melton Iii LJ, Crowson CS, Khosla S, Wilson DM, O’Fallon WM (1998) Fracture risk among patients with urolithiasis: a population-based cohort study. Kidney Int 53:459–464 Vogiatzi MG, MacKlin EA, Trachtenberg FL et al (2009) Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol 146:546–556 Quinn CT, Johnson VL, Kim HY et al (2011) Renal dysfunction in patients with thalassaemia. Br J Haematol 153:111–117 Ponticelli C, Musallam KM, Cianciulli P, Cappellini MD (2010) Renal complications in transfusion-dependent beta thalassaemia. Blood Rev 24:239–244 Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J, Cohen A, Neufeld E, Giardina PJ (2006) Prevalence of fractures among the thalassemia syndromes in North America. Bone 38:571–575 Vogiatzi MG, Macklin EA, Fung EB et al (2009) Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 24:543–557 Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B (1998) High prevalence of low bone mass in thalassaemia major. Br J Haematol 103:911–915 Fung EB, Vichinsky EP, Kwiatkowski JL, Huang J, Bachrach LK, Sawyer AJ, Zemel BS (2011) Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone 48:1305–1312 Ladis V, Raptou P, Rigatou E, Chouliaras G, Galanos A, Korres D, Kattamis C (2008) Study of bone density by pQCT analysis in healthy adults and patients with B-thalassemia major and intermedia. Pediatr Endocrinol Rev 6:127–131 Ladis VA, Gandaifis N, Papadopoulos EC, Gavras GM, Papassotiriou I, Korres DS, Kattamis CA (2004) Bone density study at the distal radius, using pQCT analysis, in Greek thalassemic patients. Pediatr Endocrinol Rev 2:307–309 Knowelden J, Buhr AJ, Dunbar O (1964) Incidence of fractures in persons over 35 years of age. A report to the M.R.C. working party on fractures in the elderly. Br J Prev Soc Med 18:130–141 Mahachoklertwattana P, Pootrakul P, Chuansumrit A, Choubtum L, Sriphrapradang A, Sirisriro R, Rajatanavin R (2006) Association between bone mineral density and erythropoiesis in Thai children and adolescents with thalassemia syndromes. J Bone Miner Metab 24:146–152 Stamatelou KK, Francis ME, Jones CA, Nyberg LM Jr, Curhan GC (2003) Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 63:1817–1823 Taylor EN, Stampfer MJ, Curhan GC (2005) Obesity, weight gain, and the risk of kidney stones. JAMA 293:455–462 Daudon M, Lacour B, Jungers P (2006) Influence of body size on urinary stone composition in men and women. Urol Res 34:193–199 Jackson RD, LaCroix AZ, Gass M et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683 Curhan GC, Willett WC, Knight EL, Stampfer MJ (2004) Dietary factors and the risk of incident kidney stones in younger women: nurses’ health study II. Arch Intern Med 164:885–891 Heaney RP (2008) Calcium supplementation and incident kidney stone risk: a systematic review. J Am Coll Nutr 27:519–527 Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ (1997) Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 126:497–504 Favus MJ (2011) The risk of kidney stone formation: the form of calcium matters. Am J Clin Nutr 94:5–6 Pak CY (1969) Physicochemical basis for formation of renal stones of calcium phosphate origin: calculation of the degree of saturation of urine with respect to brushite. J Clin Invest 48:1914–1922 Prié D, Ravery V, Boccon-Gibod L, Friedlander G (2001) Frequency of renal phosphate leak among patients with calcium nephrolithiasis. Kidney Int 60:272–276 Prié D, Huart V, Bakouh N et al (2002) Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 347:983–991 Yacobovich J, Stark P, Barzilai-Birenbaum S, Krause I, Pazgal I, Yaniv I, Tamary H (2010) Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol 32:564–567 Milat F, Wong P, Fuller PJ, Johnstone L, Kerr PG, Doery JCG, Strauss BJ, Bowden DK (2012) A case of hypophosphatemic osteomalacia secondary to deferasirox therapy. J Bone Miner Res 27:219–222 Borgna-Pignatti C, Rugolotto S, De Stefano P et al (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89:1187–1193 Cappellini MD, Cohen A, Piga A et al (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 107:3455–3462 Rheault MN, Bechtel H, Neglia JP, Kashtan CE (2011) Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer 56:674–676 Wei HY, Yang CP, Cheng CH, Lo FS (2011) Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months. Transfusion 51:949–954